Various 'dendritic cell antigens are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes

Immunotherapy

Volumn 3, Issue 9, 2011, Pages 1113-1124

  Dreyssig, Julia ^a   Kremser, Andreas ^a   Liepert, Anja ^a   Grabrucker, Christine ^a   Freudenreich, Markus ^a   Schmid, Christoph ^b   Kroell, Tanja ^a   Scholl, Nina ^a   Tischer, Johanna ^a   Kufner, Stephany ^a   Salih, Helmut ^c   Kolb, Hans Jochem ^a,d   Schmetzer, Helga Maria ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Municipal Hospital   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

acute myeloid leukemia; dendritic cells; flow cytometry; myelodysplastic syndrome; serum free culture; surface marker

Indexed keywords

B7 ANTIGEN; CD137 LIGAND; CD1B ANTIGEN; CD1C ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CELL ANTIGEN; T6 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD25+ T LYMPHOCYTE; CELL CULTURE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; LECTINS, C-TYPE; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; MALE; MANNOSE-BINDING LECTINS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES;

EID: 80053035393     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.108     Document Type: Article

References (45)

1. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin. Proc. 81, 247-260 (2006). (Pubitemid 43205780)
2. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079-2088 (1997). (Pubitemid 27132124)
3. Kremser A, Dreybig J, Grabrucker C et al. Dendritic cells can be successfully generated from leukemic blasts in individual patients with AML and MDS: an evaluation of different methods . J. Immunother. 33, 185-199 (2010).
4. Roddie H, Klammer M, Thomas C et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br. J. Haematol. 133, 152-157 (2006).
5. Roddie PH, Horton Y, Turner ML. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1. Leukemia 16, 84-93 (2002). (Pubitemid 34105603)
6. Athanasas-Platsis S, Savage NW, Winning TA, Walsh LJ. Induction of the CD1a Langerhans cell marker on human monocytes. Arch. Oral Biol. 40, 157-160 (1995).
7. Van R, Koets IAP, Im JS et al. The bovine CD1 family contains group 1 CD1 proteins, but no functional CD1d. J. Immunol. 176, 4888-4893 (2006).
8. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Ann. Rev. Immunol. 18, 767-811 (2000). (Pubitemid 30365397)
9. Hirano N, Butler MO, Xia Z et al. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 107, 1528-1536 (2006). (Pubitemid 43242391)
10. Wollenberg A, Mommaas M, Oppel T, Schottdorf EM, Gunther S, Moderer M. Expression and function of the mannose receptor CD206 on epidermal dendritic cells in inflammatory skin diseases. J . Invest. Dermatol. 118, 327-334 (2002). (Pubitemid 34158489)
11. Engering AJ, Cella M, Fluitsma D et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur. J. Immunol. 27, 2417-2425 (1997). (Pubitemid 27404329)
12. von Bergwelt-Baildon MS, Popov A, Saric T et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108, 228-237 (2006). (Pubitemid 43990633)
13. Salih HR, Nuessler V, Denzlinger C, Starling GC, Kiener PA, Schmetzer HM. Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome. Leuk. Lymphoma 45, 301-308 (2004). (Pubitemid 38181432)
14. Cheuk AT, Mufti GJ, Guinn BA. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther. 11, 215-226 (2004). (Pubitemid 38280524)
15. Bell D, Young JW, Banchereau J. Dendritic cells. Adv. Immunol. 72, 255-324 (1999). (Pubitemid 30224829)
16. Rogers NJ, Game DS, Camara NO, Jackson IM, Lombardi G, Lechler RI. Distinct effects of CD86-mediated costimulation on resting versus activated human CD4+ T cells. Eur. J. Immunol. 35, 2909-2919 (2005). (Pubitemid 41555086)
17. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9, 10-16 (1997). (Pubitemid 27095893)
18. Pietschmann P, Stockl J, Draxler S, Majdic O, Knapp W. Functional and phenotypic characteristics of dendritic cells generated in human plasma supplemented medium. Scand. J. Immunol. 51, 377-383 (2000). (Pubitemid 30212280)
19. Schmetzer HM, Kremser A, Loibl J, Kroell T, Kolb HJ. Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia 21, 1338-1341 (2007). (Pubitemid 46831833)
20. Bennett JM, Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 10(Suppl. 1), 258-269 (2005). (Pubitemid 41825739)
21. Hayhoe FG. Classification of acute leukaemias. Blood Rev. 2, 186-193 (1998).
22. Mitelman F. Guidelines for cancer cytogenetics, supplement to: An International System for Human Cytogenetic Nomenclature. S Karger, Basel, Switzerland (1995).
23. Campana D, Behm FG. Immunophenotyping of leukemia. J. Immunol. Methods 243, 59-75 (2000).
24. Kufner S, Zitzelsberger H, Kroell T et al. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions. Scand. J. Immunol. 62, 86-98 (2005).
25. Grabrucker C, Liepert A, Dreyssig J et al. The quality and quantity of leukemia-derived dendritic cells (DC) from patients with acute myeloid leukaemia and myelodysplastic syndrom are a predictive factor for the lytic potential of DC-primed leukemia-specific T cells. J. Immunother. 33(5), 523-537 (2010).
26. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86, 2041-2050 (1995).
27. Houtenbos I, Westers TM, Stam AG et al. Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation. Cancer Immunol. Immunother. 52, 455-462 (2003). (Pubitemid 36831367)
28. Schmid C, Schleuning M, Schwerdtfeger R et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108, 1092-1099 (2006). (Pubitemid 44154650)
29. Gilboa E. DC-based cancer vaccines. J. Clin. Invest. 117, 1195-1203 (2007). (Pubitemid 46718404)
30. Gao L, Bellantuono I, Elsasser A et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95, 2198-2203 (2000). (Pubitemid 30167714)
31. Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. Immunobiology 211, 677-685 (2006).
32. Lee AW, Truong T, Bickham K et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20(Suppl. 4), A8-A22 (2002). (Pubitemid 35449402)
33. Westers TM, Stam AG, Scheper RJ et al. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia. Cancer Immunol. Immunother. 52, 17-27 (2003). (Pubitemid 36177222)
34. Graf M, Reif S, Hecht K et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).Ann. Hematol. 84, 287-297 (2005). (Pubitemid 41166822)
35. Brigl M, Brenner MB. CD1: antigen presentation and T-cell function. Ann. Rev. Immunol. 22, 817-890 (2004). (Pubitemid 38680443)
36. Tobiasova-Czetoova Z, Palmborg A, Lundqvist A et al. Effects of human plasma proteins on maturation of monocyte-derived dendritic cells. Immunol. Lett. 100, 113-119 (2005). (Pubitemid 41262008)
37. Chen D, Zhang N, Fu S et al. CD4+ CD25+ regulatory T cells inhibit the islet innate immune response and promote islet engraftment. Diabetes 55, 1011-1021 (2006). (Pubitemid 44100176)
38. Salih HR, Schmetzer HM, Burke C et al. Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J. Immunol. 167, 4059-4066 (2001). (Pubitemid 32910853)
39. Kufner S 2nd, Fleischer RP, Kroell T et al. Serum-free generation and quantification of functionally active leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol. Immunother. 54, 953-970 (2005). (Pubitemid 41199791)
40. Kharfan-Dabaja M, Ayala E, Lindner I et al. Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals. Cancer Immunol. Immunother. 54, 25-36 (2005). (Pubitemid 40064482)
41. Naito K, Ueda Y, Itoh T et al. Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity. Int. J. Oncol. 28, 1481-1489 (2006).
42. Liepert A, Grabrucker C, Kremser A et al. Quality of T cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. Cell. Immun. 265, 23-30 (2010).
43. Schmetzer H. Antileukemic T-cell-mediated immune reactions: limitations and perspectives for future therapies. Immunotherapy 3(7), 809-811 (2011).
44. Smits EL, Lee C, Hardwick N et al. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunol. Immunother.
45. Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VF. Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum. Vaccin. 7(5), 579-584 (2011).